J. Pérez-García

发表

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

E. Van Cutsem, J. Tabernero, L. Paz-Ares, 2014, Clinical Cancer Research.

Status of PI3K inhibition and biomarker development in cancer therapeutics.

J. Baselga, J. Tabernero, J. Pérez-García, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

Michael G. Kharas, A. Bergamaschi, S. Chandarlapaty, 2015, Science Translational Medicine.

Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).

P. Nuciforo, R. Dienstmann, E. Zamora, 2016 .

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases

J. Pérez-García, A. Llombart-Cussac, J. Cortés, 2019, Orphanet Journal of Rare Diseases.

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

S. Loi, S. Loibl, F. André, 2019, Clinical Cancer Research.

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

J. Pérez-García, T. Pluard, F. Ademuyiwa, 2018, The Lancet. Oncology.

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge

J. Pérez-García, J. Cortés, A. Llombart, 2020, Cancers.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

R. Bernards, C. Caldas, Mariette Schrier, 2019, Clinical Cancer Research.

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)

J. Pérez-García, A. Llombart-Cussac, J. Cortés, 2020, International journal of environmental research and public health.

Advances in targeted therapies for metastatic colorectal cancer

F. J. Ramos, M. Ruiz-Echarri, J. Tabernero, 2009 .

New approaches and targets in advanced colorectal cancer.

F. J. Ramos, M. Ruiz-Echarri, J. Tabernero, 2009, European journal of cancer.

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.

F. Marmé, J. Pérez-García, A. Prat, 2021, The Lancet. Oncology.

Adjuvant bevacizumab: positive data from a negative trial.

J. Pérez-García, J. Cortés, 2013, The Lancet. Oncology.

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

J. Pérez-García, T. Suter, S. Di Cosimo, 2020, Cancers.

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.

J. Tabernero, J. Pérez-García, E. Vilar, 2007, Endocrine-related cancer.

Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.

J. Pérez-García, J. Cortés, O. Metzger Filho, 2018, The oncologist.

The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.

J. Pérez-García, S. Im, P. Schmid, 2017, Cancer treatment reviews.

The beautiful history of pertuzumab.

J. Pérez-García, J. Cortés, E. Muñoz-Couselo, 2012, Expert review of anticancer therapy.

NRAS-mutant melanoma: current challenges and future prospect

J. Pérez-García, E. Muñoz-Couselo, Ester Zamora Adelantado, 2017, OncoTargets and therapy.

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin

J. Brunet, S. Verdura, E. Cuyás, 2019, Front. Oncol..

Challenges in Prognosis, Systemic Therapy, and Survival in Patients with HER2-Negative Metastatic Breast Cancer candidates to systemic chemotherapy

S. Cosimo, C. Barrios, J. Pérez-García, 2017 .

Bone metastases: Causes, consequences and therapeutic opportunities

J. Pérez-García, J. Cortés, E. Muñoz-Couselo, 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma

J. Pérez-García, J. Cortés, J. Palacios, 2020, Cancers.

PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).

J. Baselga, J. Tabernero, R. Dienstmann, 2012 .

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

S. Kuemmel, E. Hitre, J. Pérez-García, 2021, Breast Cancer Research and Treatment.

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

J. Pérez-García, R. Andrés, A. Prat, 2019, BMC Medicine.

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

J. Brunet, S. Verdura, E. Cuyás, 2019, Aging.

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.

G. Curigliano, J. Pérez-García, A. Prat, 2021, European journal of cancer.

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

J. Pérez-García, A. Llombart-Cussac, A. Alonso-Fernández, 2022, International Journal of Infectious Diseases.